More payers could stanch off-label use of Ozempic

According to a report in The Washington Post last week, some 14 Anthem Blue Cross Blue Shield plans cautioned healthcare providers in several states about prescribing Ozempic to non-diabetic patients. As the “education” letter noted, an inquiry undertaken of those physicians’ claims by the plan’s “Special Investigations Unit” revealed that 60% of patients prescribed Ozempic lacked “sufficient evidence” of diabetes, the product’s Food and Drug Administration-approved use.M